Immunosuppression with FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 1, 2016, Pages 47-56

  Luk, Fu Sang ^a   Kim, Roy Y ^a   Li, Kang ^a   Ching, Daniel ^a   Wong, David K ^a   Joshi, Sunil K ^a   Imhof, Isabella ^a   Honbo, Norman ^a   Hoover, Holly ^a   Zhu, Bo Qing ^a   Lovett, David H ^a   Karliner, Joel S ^a   Raffai, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ApoE; cardioprotection; coronary atherosclerosis; FTY720; heart failure; immunosuppression; S1P

Indexed keywords

APOENZYME; CHOLESTEROL; FINGOLIMOD; GELATINASE A; GELATINASE B; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; LIPID; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; APOLIPOPROTEIN E; IMMUNOSUPPRESSIVE AGENT; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTRON; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUOIA; T LYMPHOCYTE; TETRATRICOPEPTIDE REPEAT; TRANSTHORACIC ECHOCARDIOGRAPHY; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; CORONARY ARTERY DISEASE; DEFICIENCY; GENE EXPRESSION REGULATION; LIPID DIET; METABOLISM; MORTALITY; MYOCARDIAL INFARCTION; SURVIVAL RATE; TRANSGENIC MOUSE; TRENDS;

ANIMALS; APOLIPOPROTEINS E; CORONARY ARTERY DISEASE; DIET, HIGH-FAT; FINGOLIMOD HYDROCHLORIDE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; SCAVENGER RECEPTORS, CLASS B; SURVIVAL RATE;

EID: 84954289755     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000312     Document Type: Article

References (42)

1. Dixon JA, Spinale FG. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011;73:47-68.
2. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation. 1976;53(3 suppl):I204-I206.
3. Frangogiannis NG. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol. 2014;63:185-195.
4. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res. 2014;102:240-248.
5. Zouggari Y, Ait-Oufella H, Bonnin P, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19:1273-1280.
6. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol. 2015.
7. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015; 131:1019-1030.
8. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta. 2013;1831:203-212.
9. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295-298.
10. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105.
11. Jin ZQ, Zhang J, Huang Y, et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007;76:41-50.
12. Liu W, Zi M, Naumann R, et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation. 2011;124:2702-2715.
13. Liu W, Zi M, Tsui H, et al. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail. 2013;6:833-844.
14. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of highdensity lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201-211.
15. Vessey DA, Kelley M, Li L, et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit. 2006;12:Br318-Br324.
16. Keul P, Lucke S, von Wnuck Lipinski K, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108:314-323.
17. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Circulation. 2007;115: 501-508.
18. Wang G, Kim RY, Imhof I, et al. The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol. 2014;63:132-143.
19. Zhang S, Picard MH, Vasile E, et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation. 2005;111:3457-3464.
20. Eberle D, Luk FS, Kim RY, et al. Inducible ApoE gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile. Arterioscler Thromb Vasc Biol. 2013;33:1759-1767.
21. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2005;25:436-441.
22. Raffai RL, Weisgraber KH. Hypomorphic apolipoprotein E mice: a new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J Biol Chem. 2002;277:11064-11068.
23. Eberle D, Kim RY, Luk FS, et al. Apolipoprotein E4 domain interaction accelerates diet-induced atherosclerosis in hypomorphic Arg-61 apoe mice. Arterioscler Thromb Vasc Biol. 2012;32:1116-1123.
24. Gaudreault N, Kumar N, Posada JM, et al. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler Thromb Vasc Biol. 2012;32:264-272.
25. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-613.
26. Alfonso-Jaume MA, Bergman MR, Mahimkar R, et al. Cardiac ischemiareperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol. 2006;291:H1838-H1846.
27. Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1847-H1860.
28. Wang GY, Bergman MR, Nguyen AP, et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res. 2006;69:688-696.
29. Zhou HZ, Ma X, Gray MO, et al. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun. 2007;358:189-195.
30. Lovett DH, Mahimkar R, Raffai RL, et al. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One. 2012;7:e34177.
31. Lovett DH, Chu C, Wang G, et al. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Front Physiol. 2014;5:363.
32. Lovett DH, Mahimkar R, Raffai RL, et al. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One. 2013;8:e68154.
33. Sun W, Liu DB, Li WW, et al. Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Int J Oncol. 2014;44:1551-1560.
34. Zhou X, Ren Y, Liu A, et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 2014;31:2173-2180.
35. Mukherjee R, Mingoia JT, Bruce JA, et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H2216-H2228.
36. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013;112:195-208.
37. Clark IM, Swingler TE, Sampieri CL, et al. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40: 1362-1378.
38. Alfonso-Jaume MA, Mahimkar R, Lovett DH. Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochem J. 2004;380:735-747.
39. Hadler-Olsen E, Fadnes B, Sylte I, et al. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278:28-45.
40. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325-329.
41. Zhang Y, Da Silva JR, Reilly M, et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870-2874.
42. Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015.